Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the challenges and limitations associated with the adoption of new treatments and the impact of emerging therapies on patient outcomes, quality of life, and disease management in the long term.
Ronald Oudiz, MD, FACP, FACC, FCCP
Advertisement
Articles by Ronald Oudiz, MD, FACP, FACC, FCCP
A cardiovascular specialist provides an overview of emerging therapies and targets in the PAH treatment space and how they address current unmet needs.
Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the latest guidelines and recommendations for the treatment of pulmonary arterial hypertension (PAH) and how they differ from previous versions.
Advertisement
Latest Updated Articles
Evolving Guidelines for PAH TreatmentMay 1st 2024
- New Therapeutic Frontiers in PAH
May 1st 2024
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
Tegoprubart Eases Symptom Burden vs Tacrolimus After Kidney Transplant
4
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
5